{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:34:37Z","timestamp":1790868877719,"version":"4.1.0"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:sec>\n            <jats:title>Background.<\/jats:title>\n            <jats:p>Infliximab selectively targets recently activated effector cells and, as an induction agent, might enable the safe elimination of mycophenolate from maintenance immunosuppression in kidney transplantation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods.<\/jats:title>\n            <jats:p>This is a phase II international multicenter open-label single-arm confidence interval (CI)\u2013based clinical trial of the BIO-DrIM EU consortium aimed at assessing the efficacy and safety of rabbit antithymocyte globulin and infliximab induction in kidney transplantation. Sixty-seven primary kidney transplant recipients at low risk (panel-reactive antibodies &lt;20%, no donor-specific antibodies [DSA]) received rabbit antithymocyte globulin (2\u2009\u00d7\u20091.5\u2009mg\/kg, postoperative days 0 and 1) and infliximab (5\u2009mg\/kg, postoperative day 2), followed by mycophenolate-free tacrolimus-based immunosuppression for 12 mo. The primary endpoint was efficacy failure, defined as a composite of acute rejection, graft loss, or poor graft function (estimated glomerular filtration rate &lt;40\u2009mL\/min) at 12 mo and was based on the endpoint of the comparator study. Additionally, a historical propensity-matched control cohort was established.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results.<\/jats:title>\n            <jats:p>Primary endpoint occurred in 22 of 67 patients (32.84%), with upper bound of an exact 1-sided 95% CI of 43.47%, which met the predefined criteria (efficacy failure of &lt;40% and upper-bound 95% CI of &lt;50%) and was similar in the historical matched cohort. By 12 mo, 79.1% of patients remained on the study protocol. Lower rates of BK replication (6% versus 22.4%; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2009=\u20090.013) but higher rates of de novo DSAs (11.9% versus 1.5%; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2009=\u20090.039) were observed in the study cohort.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions.<\/jats:title>\n            <jats:p>A similar efficacy of the study immunosuppression regimen to the comparator study and the historical matched cohort was found. However, a higher de novo DSA emergence points to an increased risk of antibody-mediated rejection (NCT04114188).<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/tp.0000000000004736","type":"journal-article","created":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T04:00:56Z","timestamp":1690862456000},"page":"242-251","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Tacrolimus After rATG and Infliximab Induction Immunosuppression\u2014RIMINI Trial"],"prefix":"10.1097","volume":"108","author":[{"given":"Ondrej","family":"Viklicky","sequence":"first","affiliation":[{"name":"Department of Nephrology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic."},{"name":"Transplant Laboratory, Institute for Clinical and Experimental Medicine, Prague, Czech Republic."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Zahradka","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gantuja","family":"Bold","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Intensive Care, Charit\u00e9 Universit\u00e4tsmedizin Berlin, Berlin Center for Advanced Therapies (BeCAT), Berlin Institut of Health Center of Regenerative Therapies (BCRT), Berlin Institute of Health, Berlin, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriol","family":"Bestard","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Kidney Transplantation, Vall d\u2019Hebron University Hospital, Barcelona Hospital Campus, Barcelona, Spain."},{"name":"Vall d\u2019Hebron Institut de Recerca (VHIR), Vall d\u2019Hebron Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Hruba","sequence":"additional","affiliation":[{"name":"Transplant Laboratory, Institute for Clinical and Experimental Medicine, Prague, Czech Republic."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie M.","family":"Otto","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Intensive Care, Charit\u00e9 Universit\u00e4tsmedizin Berlin, Berlin Center for Advanced Therapies (BeCAT), Berlin Institut of Health Center of Regenerative Therapies (BCRT), Berlin Institute of Health, Berlin, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maik","family":"Stein","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Intensive Care, Charit\u00e9 Universit\u00e4tsmedizin Berlin, Berlin Center for Advanced Therapies (BeCAT), Berlin Institut of Health Center of Regenerative Therapies (BCRT), Berlin Institute of Health, Berlin, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anett","family":"Sefrin","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Intensive Care, Charit\u00e9 Universit\u00e4tsmedizin Berlin, Berlin Center for Advanced Therapies (BeCAT), Berlin Institut of Health Center of Regenerative Therapies (BCRT), Berlin Institute of Health, Berlin, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Istvan","family":"Modos","sequence":"additional","affiliation":[{"name":"Information Technology Department, Institute for Clinical and Experimental Medicine, Prague, Czech Republic."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Meneghini","sequence":"additional","affiliation":[{"name":"Vall d\u2019Hebron Institut de Recerca (VHIR), Vall d\u2019Hebron Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Crespo","sequence":"additional","affiliation":[{"name":"Vall d\u2019Hebron Institut de Recerca (VHIR), Vall d\u2019Hebron Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Grinyo","sequence":"additional","affiliation":[{"name":"Department of Medicine, Barcelona University, Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Dieter","family":"Volk","sequence":"additional","affiliation":[{"name":"Berlin Center for Advanced Therapies (BeCAT) and Institute of Medical Immunology, Charit\u00e9 Universit\u00e4tsmedizin Berlin, Berlin Institut of Health Center of Regenerative Therapies (BCRT), Berlin Institute of Health, Berlin, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Christakoudi","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, St. Mary\u2019s Campus, Norfolk Place, London, United Kingdom."},{"name":"Department of Inflammation Biology, School of Immunology and Microbial Sciences, King\u2019s College London, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Reinke","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Intensive Care, Charit\u00e9 Universit\u00e4tsmedizin Berlin, Berlin Center for Advanced Therapies (BeCAT), Berlin Institut of Health Center of Regenerative Therapies (BCRT), Berlin Institute of Health, Berlin, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,8,1]]},"reference":[{"key":"R2-20250604","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/ajt.15274","article-title":"OPTN\/SRTR 2017 annual data report: kidney.","volume":"19","author":"Hart","year":"2019","journal-title":"Am J Transplant"},{"key":"R3-20250604","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1136\/bmj.318.7191.1104","article-title":"Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: meta-analysis of randomised trials.","volume":"318","author":"Knoll","year":"1999","journal-title":"BMJ"},{"key":"R4-20250604","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.2165\/00003495-200363120-00006","article-title":"Tacrolimus: a further update of its use in the management of organ transplantation.","volume":"63","author":"Scott","year":"2003","journal-title":"Drugs"},{"key":"R5-20250604","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1097\/00007890-200105150-00017","article-title":"Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation.","volume":"71","author":"Vincenti","year":"2001","journal-title":"Transplantation"},{"key":"R6-20250604","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"Reduced exposure to calcineurin inhibitors in renal transplantation.","volume":"357","author":"Ekberg","year":"2007","journal-title":"N Engl J Med"},{"key":"R7-20250604","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1681\/ASN.2014121234","article-title":"Adverse outcomes of tacrolimus withdrawal in immune-quiescent kidney transplant recipients.","volume":"26","author":"Hricik","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"R8-20250604","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1016\/j.transproceed.2019.03.061","article-title":"Clinical Significance of mycophenolate mofetil withdrawal in kidney transplant recipients.","volume":"51","author":"Park","year":"2019","journal-title":"Transplant Proc"},{"key":"R9-20250604","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1034\/j.1600-6143.2003.00123.x","article-title":"T-cell allorecognition and transplant rejection: a summary and update.","volume":"3","author":"Heeger","year":"2003","journal-title":"Am J Transplant"},{"key":"R10-20250604","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1172\/JCI38482","article-title":"Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans.","volume":"119","author":"Bruns","year":"2009","journal-title":"J Clin Invest"},{"key":"R11-20250604","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1006\/cyto.1995.0029","article-title":"Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions.","volume":"7","author":"Scallon","year":"1995","journal-title":"Cytokine"},{"key":"R12-20250604","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1053\/gast.2001.28702","article-title":"Infliximab induces apoptosis in monocytes from patients with chronic active Crohn\u2019s disease by using a caspase-dependent pathway.","volume":"121","author":"L\u00fcgering","year":"2001","journal-title":"Gastroenterology"},{"key":"R13-20250604","doi-asserted-by":"crossref","first-page":"e0169624","DOI":"10.1371\/journal.pone.0169624","article-title":"Sequential targeting of CD52 and TNF allows early minimization therapy in kidney transplantation: from a biomarker to targeting in a proof-of-concept trial.","volume":"12","author":"Viklicky","year":"2017","journal-title":"PLoS One"},{"key":"R14-20250604","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1681\/ASN.2022040454","article-title":"Infliximab induction lacks efficacy and increases BK virus infection in deceased donor kidney transplant recipients: results of the CTOT-19 trial.","volume":"34","author":"Hricik","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"R15-20250604","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1097\/TP.0b013e3182a203bd","article-title":"OSAKA trial: a randomized, controlled trial comparing tacrolimus QD and BD in kidney transplantation.","volume":"96","author":"Albano","year":"2013","journal-title":"Transplantation"},{"key":"R16-20250604","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/j.1600-6143.2008.02159.x","article-title":"Banff 07 classification of renal allograft pathology: updates and future directions.","volume":"8","author":"Solez","year":"2008","journal-title":"Am J Transplant"},{"key":"R17-20250604","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v042.i08","article-title":"MatchIt: nonparametric preprocessing for parametric causal inference.","volume":"42","author":"Ho","year":"2011","journal-title":"J Statistical Software"},{"key":"R18-20250604","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v042.i07","article-title":"Multivariate and propensity score matching software with automated balance optimization: the matching package for R.","volume":"42","author":"Sekhon","year":"2011","journal-title":"J Statistical Software"},{"key":"R20-20250604","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/neuonc\/nox030","article-title":"Point\/counterpoint: randomized versus single-arm phase II clinical trials for patients with newly diagnosed glioblastoma.","volume":"19","author":"Grossman","year":"2017","journal-title":"Neuro Oncol"},{"key":"R21-20250604","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/pst.1726","article-title":"Do single-arm trials have a role in drug development plans incorporating randomised trials?","volume":"15","author":"Grayling","year":"2016","journal-title":"Pharm Stat"},{"key":"R22-20250604","doi-asserted-by":"crossref","first-page":"10137","DOI":"10.3389\/ti.2022.10137","article-title":"Rationale for surrogate endpoints and conditional marketing authorization of new therapies for kidney transplantation.","volume":"35","author":"Naesens","year":"2022","journal-title":"Transpl Int"},{"key":"R23-20250604","doi-asserted-by":"crossref","first-page":"8","DOI":"10.6030\/1939-067X-3.1.8","article-title":"Clinical trial structures.","volume":"3","author":"Evans","year":"2010","journal-title":"J Exp Stroke Transl Med"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000004736","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T18:20:23Z","timestamp":1749061223000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000004736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,1]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000004736","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,1]]}}}